Item 1.01. Entry into a Material Definitive Agreement.

On January 5, 2021, Silo Pharma, Inc. (the "Company") entered into a entered into an investigator-sponsored study agreement (the "Agreement") with the University of Maryland, Baltimore ("UMB"). The research project is a clinical study to examine a novel peptide-guided drug delivery approach for the treatment of multiple sclerosis. More specifically, the study is designed to evaluate (1) whether MS-1-displaying liposomes can effectively deliver dexamethasone to the CNS and (2) whether MS-1-displaying liposomes are superior to plain liposomes, also known as free drug, in inhibiting the relapses and progression of EAE. Pursuant to the Agreement, the Project Work (as defined in the Agreement) shall commence on March 1, 2021 and will continue until substantial completion, subject to renewal upon mutual written consent of the parties.

The foregoing summary of the Agreement does not purport to be complete and is qualified in its entirety by reference to the Agreement which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is hereby incorporated by reference.

Item 9.01. Financial Statements and Exhibits.





Exhibits



Exhibit No.   Description
   10.1         Sponsored Research Agreement by and between the Company and the
              University of Maryland, Baltimore




  -1-

© Edgar Online, source Glimpses